stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Revenue growth
Denali Therapeutics Inc.'s revenue growth over the twelve months to 30 September 2026 was −93.4%, down 298.1 percentage points from fiscal 2023 (204.7%). Over the past ten years it has ranged from −85.5% (fiscal 2021) to 1,158.2% (fiscal 2020); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2023 | 204.7% | 81.84 |
| FY2022 | 122.9% | 208.40 |
| FY2021 | −85.5% | (1,243.69) |
| FY2020 | 1,158.2% | 1,237.53 |
| FY2019 | −79.3% | (463.48) |
| FY2018 | 384.1% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −94.0% | (4.22) |
| Jun 2026 | −89.7% | 10.26 |
| Dec 2023 | −100.0% | (35.60) |
| Sep 2023 | −64.4% | (524.85) |
| 22 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | 86.3% |
| VRDN Viridian Therapeutics, Inc. compare | −62.8% |
| IDYA IDEAYA Biosciences, Inc. compare | −83.6% |
| DNLI Denali Therapeutics Inc. | −93.4% |
| VKTX Viking Therapeutics, Inc. compare | — |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement